

2021 Subject Index

12-core prostate biopsy scheme	19	Emergency	276
5-hydroxyuracil incision	45	Endoscopy	236
Adenocarcinoma	196	Epstein criteria	19
Adjuvant chemotherapy	96	Fiducial marker	158
Adjuvant intraluminal therapy	129	Geriatrics	133
Adjuvant treatments	264	Germ cell testicular cancer	67
ADMA	107	Gleason grade	26
Aging	133	Glomerular filtration rates	242
AMACR/P504S	92	Google trends	142
Anxiety	7	Granulomatous orchitis	126
Arginine	107	Haematuria	34
Autologous stem-cell transplantation	258	Haematuria duration	34
Awareness month	142	Haematuria frequency	34
Base excision repair	45	Health status	73
Benign prostatic hyperplasia	71	High-risk carcinoma	219
Bilateral	56	Histology	236
Biopsy	15, 83	Hybrid tumor	273
Bladder	179	Index lesion	147
Bladder cancer	34, 40, 107, 168, 174, 206, 264	Intravesical BCG	206
Breast cancer	142	Irradiation	219
Cancer	133	L-NMMA	107
Cancer prognosis	252	Low-grade	273
Cancer-specific survival	174	Lymph node involvement	174
Case report	192	Lymphocyte	168
Castration sensitive	1	Lymphovascular invasion	174
Chemotherapy	1, 67, 258	Malignancy	126
Children	200	Malignant eccrine poroma	186
Chromophobe	273	Metachronous	56
Chromosome translocation	122	Metachronous neoplasms	49
Chronic pyelonephritis	192	Metastasectomy	270
Cisplatin	67	Metastases	231
Citrulline	107	Metastasis	270
Clinically insignificant prostate cancer	19	Metformin	162
Clinically significant prostate cancer	215	Mid-term follow-up	117
Cognitive fusion	15	MiT family carcinomas	122
Colorectal malignancies	179	MRI US Fusion	11
Comorbidity	73	MRI-ultrasound fusion	210
Complication	111	multiparametric magnetic resonance imaging	15, 147
Continence	236	Neoadjuvant chemotherapy	264
Coronavirus	206	Neoadjuvant hormonal treatment	219
COVID-19	206	Neobladder	236
Creatinine	242	Nephrectomy volume	247
Cystectomy	168	Nephrometry score	242
Detection	11	Nephron-sparing surgery	247
Diabetes mellitus	162	Neutrophil	168
Eccrine porocarcinoma	186	Non-muscle-invasive bladder cancer	45
Elderly	73	Non-tumor factors	247

2021 Subject Index

Non-urothelial bladder carcinomas	96	Sertoliform cystadenoma	189
Oncocytic tumor	273	Sexual function.....	138
Oncological outcomes	96	Side effects	162
Overall survival	174, 252	Signet-ring cell carcinoma	196
Pain score	7	Spontaneous.....	276
Pandemic	206	Standard biopsy prostate cancer	15
Paratesticular rhabdomyosarcoma	200	Stereotactic	158
Partial cystectomy.....	196	Stroke.....	67
Partial nephrectomy	111, 242	Surgical margin positivity.....	231
Pediatric	189	Surgical technique	153
Peritoneal metastases.....	179	Surgical treatment	247
PI-RADS	147	Survival.....	117
Poroid neoplasm.....	186	Sweat gland tumour	186
Positive surgical margin.....	26	Synchronous.....	56
Predictors	111	Synchronous neoplasms	49
Preoperative	276	Systemic immune-inflammation index	252
Progression	40, 45	Targeted biopsy	11, 210
Prostate biopsy	11, 87, 138, 210	Testicle	126
Prostate cancer .. 1, 11, 19, 83, 87, 92, 73, 142, 153, 158, 162, 210, 219, 225, 231, 264, 270		Testicular cancer	252, 264
Prostate neoplasms	147	Testicular dysgenesis syndrome.....	56
Prostate-specific antigen	215	Testicular germ cell tumors	258
PSA	92	Testicular germ cell tumour.....	56
PSA density.....	215	Testis tumors	200
Questionnaire.....	133	Testis-sparing surgery.....	189, 200
Radical cystectomy	96	Thromboembolism	67
Radical inguinal orchiectomy	200	Translocation renal cell carcinoma.....	122
Radical nephrectomy	276	Transrectal ultrasound-guided prostate biopsy	7
Radical prostatectomy	19, 26, 87, 147, 219, 225, 231, 280	Treatment.....	1
Radiotherapy	158, 162, 225, 258	Unclassified renal cell carcinoma.....	117
Recurrence	40, 270	Upgrading	87
Recurrence-free survival	231	Upper urinary tract urethelial tumor	129
Renal cell cancer	111	Ureter	179
Renal cell carcinoma	49, 117, 122, 186, 247, 273	Urinary bladder.....	196
Renal mass.....	192	Urodynamic.....	236
Renal tumor.....	242	Urological cancers.....	280
Renal-sparing approach	129	Ventriculoperitoneal shunt	280
Resection	179	Visual analog score	138
Resection technique.....	111	Vitamin D	83
Retropubic radical prostatectomy	153	Wilms tumor.....	276
Risk factors.....	40	Xp11 translocation	122
Robotic assisted laparoscopic prostatectomy.....	71	Yolk sac tumor	200
Robotic prostatectomy.....	153		
Robotic surgery.....	71, 280		
Rupture	276		
SDMA.....	107		
Seconder primary malignant tumour	49		